eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026

Rhea-AI Summary

eXoZymes (NASDAQ:EXOZ) will host a live webinar and conference call on Thursday, August 20, 2026, at 5:00 PM Eastern Time to discuss its second quarter 2026 results. A detailed press release on the quarter will be issued before the call.

CEO Michael Heltzen and select members of the management team will review recent developments, ongoing initiatives and anticipated milestones, followed by a Q&A session. Investors can pre-register for the webinar or access the live event via eXoZymes’ investor relations website.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced the plan to host a webinar on Thursday, August 20, 2026, at 5:00 PM Eastern Time to discuss its results for the second quarter 2026. A press release detailing these results will be issued prior to the call.

LOS ANGELES, CA / ACCESS Newswire / August 11, 2026 / CEO of eXoZymes, Michael Heltzen, will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer period.

Investors can pre-register for the webinar HERE.

On the day of the event, the live webinar can also be accessed through eXoZymes' investor relations website at https://exozymes.com/investor.

About eXoZymes
Founded in 2019, eXoZymes is pioneering a cell-free biomanufacturing platform that uses AI-enhanced enzymes - called exozymes - to make valuable natural products and new analogs outside living cells. The company's platform is designed to replace inefficient extraction and petrochemical processes with a scalable way to produce high-value molecules for nutraceutical and pharmaceutical markets.

eXoZymes is building a portfolio of biosolutions across NCT, cannabinoid analogs, santalene, and other high-value natural product molecules, with potential commercialization paths that include partnerships, licensing and joint ventures. Learn more at exozymes.com.

eXoZymes Safe Harbor
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely," "potential," or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of eXoZymes' quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.

eXoZymes contact
Lasse Görlitz, VP of Comms & IR
(858) 319-7135
press@exozymes.com

LinkedIn | X | YouTube

SOURCE: eXoZymes

View the original press release on ACCESS Newswire

FAQ

When is the eXoZymes (NASDAQ:EXOZ) Q2 2026 earnings update conference call?

The eXoZymes Q2 2026 update call will be held on Thursday, August 20, 2026, at 5:00 PM Eastern Time. According to eXoZymes, a press release with second quarter 2026 results will be issued before the webinar begins.

How can investors access the eXoZymes (EXOZ) second quarter 2026 webinar?

Investors can access the eXoZymes Q2 2026 webinar via the company’s investor relations website at https://exozymes.com/investor. According to eXoZymes, participants may also pre-register for the webinar using the provided registration link ahead of the live event.

Who will host the eXoZymes (EXOZ) Q2 2026 conference call and what will be discussed?

CEO Michael Heltzen will lead the eXoZymes Q2 2026 call, joined by select management team members. According to eXoZymes, they plan to review recent developments, ongoing initiatives, anticipated milestones and then host a question-and-answer session for investors.

What will eXoZymes (NASDAQ:EXOZ) cover in its Q2 2026 results update?

eXoZymes will discuss its second quarter 2026 results, recent company developments and key initiatives. According to eXoZymes, management also intends to outline anticipated milestones and provide time for a Q&A segment with participating investors during the webinar.

What does eXoZymes (EXOZ) do in the AI-enhanced enzyme and biomanufacturing space?

eXoZymes develops a cell-free biomanufacturing platform using AI-enhanced enzymes, called exozymes, to produce valuable natural products. According to eXoZymes, its platform aims to replace inefficient extraction and petrochemical processes for nutraceutical and pharmaceutical molecules.

Which markets and product areas is eXoZymes (EXOZ) targeting with its biosolutions portfolio?

eXoZymes is targeting nutraceutical and pharmaceutical markets with high-value natural product molecules. According to eXoZymes, its portfolio focuses on NCT, cannabinoid analogs, santalene and other natural products, with commercialization paths including partnerships, licensing and joint ventures.